Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darovasertib + crizotinib versus investigator’s choice first-line therapy in HLA-A2 negative metastatic uveal melanoma
2023-506686-66-01Phase 3Authorised
- Sponsor
- IDEAYA Biosciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of darovasertib and crizotinib in intraocular melanoma (2 arms), sponsored by IDEAYA Biosciences. Primary endpoints: Dose-exposure-response relationship, Pharmacokinetics and 3 more. Planned start Aug 2024; status: authorised.
02
Drugs
darovasertibcrizotinib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2023-506686-66-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506686-66-01.